Leukemia treatment break: a new hope for AML patients in remission
NCT ID NCT06511882
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 27 times
Summary
This study looks at whether people with acute myeloid leukemia (AML) whose cancer is well-controlled by a combination of two drugs (azacitidine or decitabine plus venetoclax) can safely stop treatment for a while after one year. The goal is to see if they can stay in remission without the cancer coming back. About 37 adults who have achieved a deep remission (negative measurable residual disease) will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.